Answers are grounded in this paper and cite their sources.
This Viewpoint analyzes how the NCCN’s boxed statement that all cancer is best managed in a clinical trial cannot be applied to all patients and calls for its removal from its clinical practice guidelines.
No takes yet. Share an insight, caveat, or question.
Shalowitz et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: